Welcome to our dedicated page for Clinuvel Pharmaceuticals SEC filings (Ticker: CLVLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clinuvel Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clinuvel Pharmaceuticals's regulatory disclosures and financial reporting.
Clinuvel Pharmaceuticals provided a commercial update on vitiligo, outlining benchmarks for current therapies and the development of its lead melanocortin drug SCENESSE® (afamelanotide) with adjunct narrowband UVB (NB-UVB) as a systemic repigmentation approach for patients with extensive disease affecting at least 10% of body surface area.
The update reviews published response rates for NB-UVB and topical and oral Janus kinase (JAK) inhibitors, then notes early CUV105 data showing visible, lasting repigmentation in 12 SCENESSE® plus NB-UVB case reports and prior trials where the combination outperformed NB-UVB alone, while afamelanotide monotherapy was ineffective. Clinuvel states it has reinforced supply chains, expanded North American infrastructure, engaged more than 100 prospective Specialty Centers, anticipates CUV105 topline results in December 2026, and indicates the anticipated start of pivotal CUV107 in November 2026.
CLINUVEL PHARMACEUTICALS provided an update on the clinical and regulatory path for SCENESSE® (afamelanotide) in vitiligo. Late-stage study CUV105 has enrolled 210 darker-skinned patients (Fitzpatrick III–VI), comparing SCENESSE® plus narrowband UVB (NB-UVB) to NB-UVB alone over a 20-week treatment period, with topline results anticipated in December 2026. Key endpoints are T-VASI50 (≥50% total body repigmentation) and F-VASI75 (≥75% facial repigmentation), supported by central photographic analysis.
CUV105 will be followed by pivotal Phase III study CUV107. The European Medicines Agency reviewed the CUV107 protocol in April 2026, and it was agreed to include 300 vitiligo patients with darker skin types (Fitzpatrick IV–VI). CUV107 is anticipated to start in November 2026 with a planned 12-month recruitment, assessing repigmentation, durability of response and safety. SCENESSE® is already approved for erythropoietic protoporphyria in several regions but is not yet approved for vitiligo.
Clinuvel Pharmaceuticals Limited, a foreign private issuer, submitted a Form 6-K for July 2026 stating that it had lodged with the Australian Securities Exchange an announcement titled “Appendix 3H - Notification of cessation of securities,” which is included as Exhibit 99.1 for U.S. investors.
Clinuvel Pharmaceuticals Limited announced a strategic reorganisation under which its corporate headquarters and key functions will relocate to the United States, with changes effective 1 January 2027. Operations and resources will be refocused exclusively on the U.S. pharmaceutical pipeline, commercial strategy, and capital markets.
The plan includes a global workforce reduction of approximately 10%-20% and relocation of selected functions to the U.S. to better align operating expenditure with current revenue generation and near-term clinical and commercial priorities. Management highlights the U.S. as representing over 40% of the global pharmaceutical market by value and a primary ecosystem for premium pricing, regulatory advancement, and M&A activity.
The reorganisation reflects that over 66% of Clinuvel’s shareholder register is held by foreign investors and that late-stage programs, particularly in vitiligo, mainly target an estimated six million affected U.S. patients. Leadership states that a U.S. focus is viewed as the most effective way to realise the intrinsic value of the company’s assets and expand access to global healthcare investors.
Clinuvel Pharmaceuticals Limited reports that its American Depositary Share (ADS) began trading on the Nasdaq Stock Market on 20 July 2026 (New York time) under the ticker CUVL. This trading start completes the uplift of its previous Level I American Depositary Receipt CLVLY to a Level II ADS program.
The company is a global biopharmaceutical group focused on melanocortin peptide therapies for genetic, metabolic, and dermatological disorders. Its lead therapy SCENESSE® (afamelanotide 16mg) is approved for commercial distribution in Europe, the USA, Canada, Israel, and Australia for adult patients with erythropoietic protoporphyria (EPP).
CLINUVEL PHARMACEUTICALS LIMITED reports that its American Depositary Share (ADS) is expected to commence trading on the Nasdaq Stock Market on 20 July 2026 under the ticker CUVL, after the U.S. SEC deemed its publicly filed Form 20-F Registration Statement effective on 17 July and Nasdaq approved the listing.
The company’s existing over-the-counter ADR CLVLY will be upgraded from Level I to a Level II ADS on Nasdaq, with each ADS representing one ordinary share listed on the ASX. CLINUVEL does not propose to raise capital or issue new shares as part of this upgraded depositary share program, and current CLVLY holders are not required to take any action. CUVL will trade on the Nasdaq Global Select Market, which provides greater visibility among U.S. investors. CLINUVEL highlights this move as part of a broader shift of its business toward North America while continuing to commercialise its lead therapy SCENESSE.